Patents by Inventor Vojtech Balsanek

Vojtech Balsanek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES
    Publication number: 20230331745
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 19, 2023
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • Glucose-sensitive albumin-binding derivatives
    Patent number: 11767332
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: September 26, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • GLUCOSE SENSITIVE INSULIN DERIVATIVES
    Publication number: 20220184184
    Abstract: The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The invention also relates to novel intermediates. Finally, the invention provides a pharmaceutical composition comprising the insulin derivatives of the invention and the use of such a composition in the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Inventors: Thomas Hoeg-Jensen, Carsten Behrens, Emiliano Clo, Martin Werner Borchsenius Muenzel, Per Sauerberg, Thomas Kruse, Jane Spetzler, Ulrich Sensfuss, Claudia Ulrich Hjoerringgaard, Henning Thoegersen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES
    Publication number: 20220081451
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 17, 2022
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • Glucose-sensitive albumin-binding derivatives
    Patent number: 11186595
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X—R2, and wherein “X” is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (11a) or (IIb) Also described are diboron conjugates represented by the general Formula (I?), which is: R1?-X?—R2?, in which either the moeities R1? or R2? or X? carry a drug that is covalently attached to the diboron compound.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: November 30, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES
    Publication number: 20200325160
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X—R2, and wherein “X” is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (11a) or (IIb) Also described are diboron conjugates represented by the general Formula (I?), which is: R1?-X?—R2?, in which either the moeities R1? or R2? or X? carry a drug that is covalently attached to the diboron compound.
    Type: Application
    Filed: November 8, 2018
    Publication date: October 15, 2020
    Inventors: Thomas Kruse, Mikael Kofoed-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Vanova
  • Ligands for Aldoketoreductases
    Publication number: 20100048604
    Abstract: The present invention relates to compounds useful for detecting the activity of human aldoketoreductase 1Cs, compounds useful for competitively inhibiting human aldoketoreductase 1Cs and compounds useful for treating human aldoketoreductase 1C-related cancers, as well as pharmaceutical compositions and methods of manufacture thereof.
    Type: Application
    Filed: August 19, 2005
    Publication date: February 25, 2010
    Inventors: Dominic J. Yee, Vojtech Balsanek, Dalibor Sames